Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**naproxen sodium + pseudoephedrine** is a fixed-dose combination drug used to temporarily relieve symptoms of the common cold and flu such as nasal and sinus congestion, sinus pressure, headache, minor body aches and pains, and fever. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, inflammation, and fever by inhibiting the production of prostaglandins through cyclooxygenase (COX) enzyme blockade. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant by causing vasoconstriction of blood vessels in the nasal mucosa via agonism at adrenergic receptors, reducing swelling and congestion. This combination is typically administered orally and provides multi-symptom relief for up to 12 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naproxen sodium + pseudoephedrine.